A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1

Recruiting

Phase 2

GS-3242 & LENA Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1

Sponsor:

Gilead Sciences

Code:

NCT07645287

Conditions

HIV-1-infection

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

GS-3242 Tablet

GS-3242 Injection

Lenacapavir Tablet

Lenacapavir Injection

B/F/TAF

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-07-20. This information was provided to ClinicalTrials.gov by Gilead Sciences on 2026-07-10.